Y0001475

Piroxicam for system suitability

Synonym(s):
4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide, Piroxicam
Empirical Formula (Hill Notation):
C15H13N3O4S
CAS Number:
Molecular Weight:
331.35
MDL number:
PubChem Substance ID:
NACRES:
NA.24
Pricing and availability is not currently available.

grade

pharmaceutical primary standard

form

neat

CofA

certificate is enclosed in each package

mfr. no.

EDQM

Featured Industry

Pharmaceutical (small molecule)

format

neat

SMILES string

CN1C(C(=O)Nc2ccccn2)=C(O)c3ccccc3S1(=O)=O

InChI

1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)

InChI key

QYSPLQLAKJAUJT-UHFFFAOYSA-N

Gene Information

human ... PTGS1(5742), PTGS2(5743)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Biochem/physiol Actions

Cyclooxygenase inhibitor.

Packaging

Unit quantity: 15 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference subtance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Skull and crossbonesHealth hazard

Signal Word

Danger

Hazard Statements

Target Organs

Gastrointestinal tract

RIDADR

UN 2811 6.1 / PGIII

WGK Germany

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
C R Lee et al.
Drugs, 48(6), 907-929 (1994-12-01)
Piroxicam-beta-cyclodextrin is a complex of the established nonsteroidal antiinflammatory drug (NSAID) piroxicam and an inert cyclic macromolecule, beta-cyclodextrin. In clinical trials in patients with rheumatic diseases or pain arising from other conditions, it was as effective an analgesic as standard...
R N Brogden et al.
Drugs, 28(4), 292-323 (1984-10-01)
Piroxicam is a chemically different non-steroidal anti-inflammatory drug with a long half-life which enables it to be administered once daily. This member of the oxicam series of compounds is now well established in the treatment of rheumatoid arthritis and osteoarthritis...
Giulia Auriemma et al.
Carbohydrate polymers, 92(1), 367-373 (2012-12-12)
This paper proposes a multi-particulate drug delivery system produced by prilling technique in combination with an enteric coating. Optimization of process parameters, such as feed viscosity at nozzle, selection of cross-linker, pH of the gelling solution and cross-linking time, allows...
Kristine Holgersen et al.
Inflammatory bowel diseases, 21(2), 257-266 (2015-01-09)
Osteoporosis and fractures are common complications of inflammatory bowel disease. The pathogenesis is multifactorial and has been partly attributed to intestinal inflammation. The aim of this study was to evaluate bone status and assess the association between bone loss and...
Wanwadee Luksurapan et al.
Archives of physical medicine and rehabilitation, 94(2), 250-255 (2012-10-16)
To compare the effects of phonophoresis of piroxicam (PhP) and ultrasound therapy (UT) in patients with mild to moderate, symptomatic knee osteoarthritis (OA). A randomized, double-blind, controlled trial. Department of rehabilitation medicine, university hospital. Patients with knee OA (N=46; mean...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.